文献速递前列腺增生与排尿功能障碍男科与性医学

Rezum 术后泌尿与性功能复合结局:意大利多中心研究预测因素分析

Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-08-30

本研究回顾性分析意大利七家机构接受 Rezum 水蒸气前列腺内注射治疗的 262 例良性前列腺增生患者,随访 11 个月(IQR 5-15)。术后无 Clavien III-IV 级严重不良事件,早期并发症发生率为 39.3%,治疗失败需再干预 4 例(1.5%);理想泌尿结局达标率 52.9%,理想性功能结局达标率 87.8%。作者认为水蒸气前列腺内注射似乎是有效且安全的手术。

要点

  • 262 例随访 11 个月(IQR 5-15),无 Clavien III-IV 级严重不良事件。
  • 理想泌尿结局达标率 52.9%,理想性功能结局达标率 87.8%。
  • 治疗失败需再干预 4 例(1.5%),作者认为该术式似乎有效且安全。

核心结论

  • 在作者的研究系列中,水蒸气前列腺内注射似乎是有效且安全的手术。

研究设计与样本

  • 回顾性分析意大利七家机构所有接受 Rezum 治疗的患者,共纳入 262 例,随访 11 个月(IQR 5-15)。

主要发现

  • 无早期或晚期严重不良事件(Clavien III-IV 级)。
  • 早期并发症发生于 39.3% 的病例,包括 4 例血凝块潴留和 1 例输血。
  • 6 例(2.2%)报告急迫性尿失禁。
  • 治疗失败需再干预 4 例(1.5%)。
  • 术前顺行射精率为 56.5%,术后升至 78.2%;QoL 改善≥1 分者占 92.7%。

关键数值与推荐

  • 理想泌尿结局定义为 IPSS 改善≥50% 且 IPSS<7、峰值流速改善≥50% 和/或>15 ml/s、QoL 问卷改善≥1 分,且无围手术期重大并发症(AUR、输血)或术后尿失禁。
  • 理想性功能结局定义为术后(最近一次随访)顺行射精或射精功能无变化,且 IIEF-5 升高、稳定或最多降低 1 个等级。
  • 理想泌尿结局达标率 52.9%,理想性功能结局达标率 87.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia. METHODS: We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5. RESULTS: 262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively. CONCLUSIONS: In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Campobasso D, Siena G, Chiodini P, et al. Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostatic Dis. 2022. PMID: 36042295. doi:10.1038/s41391-022-00587-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。